IL99372A0 - Azacyclic compounds - Google Patents

Azacyclic compounds

Info

Publication number
IL99372A0
IL99372A0 IL99372A IL9937291A IL99372A0 IL 99372 A0 IL99372 A0 IL 99372A0 IL 99372 A IL99372 A IL 99372A IL 9937291 A IL9937291 A IL 9937291A IL 99372 A0 IL99372 A0 IL 99372A0
Authority
IL
Israel
Prior art keywords
azacyclic compounds
azacyclic
compounds
Prior art date
Application number
IL99372A
Other languages
English (en)
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of IL99372A0 publication Critical patent/IL99372A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL99372A 1990-09-10 1991-09-02 Azacyclic compounds IL99372A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH292790 1990-09-10

Publications (1)

Publication Number Publication Date
IL99372A0 true IL99372A0 (en) 1992-08-18

Family

ID=4244763

Family Applications (1)

Application Number Title Priority Date Filing Date
IL99372A IL99372A0 (en) 1990-09-10 1991-09-02 Azacyclic compounds

Country Status (12)

Country Link
EP (1) EP0475898A1 (fr)
JP (1) JPH04342571A (fr)
KR (1) KR920006323A (fr)
AU (1) AU8375591A (fr)
CA (1) CA2050769A1 (fr)
FI (1) FI914228A (fr)
HU (1) HUT59129A (fr)
IE (1) IE913165A1 (fr)
IL (1) IL99372A0 (fr)
NO (1) NO913542L (fr)
PT (1) PT98903A (fr)
ZA (1) ZA917143B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681067B1 (fr) * 1991-09-10 1993-12-17 Elf Sanofi Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
IE910913A1 (en) * 1990-03-20 1991-09-25 Sanofi Sa N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them
US5164403A (en) * 1991-04-05 1992-11-17 G. D. Searle & Co. N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
WO1992020662A1 (fr) * 1991-05-10 1992-11-26 Merck & Co., Inc. Derives acides d'aralkyltriazole actifs en tant qu'antagonistes de l'angiotensine ii
US5436259A (en) * 1991-05-10 1995-07-25 Merck & Co., Inc. Substituted 1,2,4-triazolin-3-one compounds bearing acidic functional groups as balanced angiotensin II antagonists
WO1993004046A1 (fr) * 1991-08-19 1993-03-04 E.I. Du Pont De Nemours And Company Derives d'imidazolinone d'inhibition de l'action de l'angiotensine ii au niveau de ses recepteurs
WO1993004045A1 (fr) * 1991-08-19 1993-03-04 E.I. Du Pont De Nemours And Company Derives d'imidazolinone d'inhibition de l'action de l'angiotensine ii sur ses recepteurs
US5182288A (en) * 1991-11-13 1993-01-26 Ortho Pharmaceutical Corporation Substituted n-biphenylyl lactams
DE69328108D1 (de) * 1992-10-13 2000-04-20 Searle & Co N-arylheteroarylalkyl-1-phenyl-imidazol-2-on verbindungen bei der behandlung von zirkulatorischen störungen
US5411641A (en) * 1993-11-22 1995-05-02 E. I. Du Pont De Nemours And Company Electrochemical conversion of anhydrous hydrogen halide to halogen gas using a cation-transporting membrane
FR2725987B1 (fr) * 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
US5728834A (en) * 1996-11-14 1998-03-17 Wyckoff Chemical Company, Inc. Process for preparation of 4-aryl-1,2,4-triazol-3-ones
FR2766821A1 (fr) * 1997-07-29 1999-02-05 Sanofi Sa Derives de 1,3-oxazolinyl-biphenyle, leur procede de preparation et leur utilisation comme intermediaires de synthese
GB9716446D0 (en) * 1997-08-05 1997-10-08 Agrevo Uk Ltd Fungicides
US6162922A (en) * 1998-01-30 2000-12-19 Bristol-Myers Squibb Co. Method for preparing N-substituted heterocyclic derivatives using a phase-transfer catalyst
AU4933199A (en) 1998-08-03 2000-02-28 Sumitomo Chemical Company, Limited Triazolone derivatives, use thereof, and intermediate therefor
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
US6919343B2 (en) 2002-02-08 2005-07-19 Merck & Co., Inc. N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives
ATE316954T1 (de) * 2002-02-08 2006-02-15 Merck & Co Inc N-biphenylmethylaminocycloalkancarboxamid- derivative
CA2495914A1 (fr) 2002-08-29 2004-03-11 Merck & Co., Inc. Derives n-biarylmethyl aminocycloalcanecarboxamide
AU2003242984A1 (en) * 2003-04-07 2004-11-01 Hetero Drugs Limited A novel crystalline form of irbesartan
AU2004265300A1 (en) 2003-08-07 2005-02-24 Merck & Co., Inc. Sulfonyl substituted N-(biarylmethyl) aminocyclopropanecarboxamides
US20090286990A1 (en) * 2004-05-20 2009-11-19 Reguri Buchi Reddy Process for preparing irbesartan
EP1749828A1 (fr) 2005-08-04 2007-02-07 Farmaprojects S.L. Procédé pour la préparation d'un récepteur de l'angiotensine II
WO2007052301A2 (fr) * 2005-08-31 2007-05-10 Alembic Limited Procede de preparation d'irbesartan
AU2006307471A1 (en) 2005-10-28 2007-05-03 Alembic Limited An improved process for preparation of irbesartan
WO2007122508A2 (fr) * 2006-04-24 2007-11-01 Aurobindo Pharma Limited Procédé amélioré de préparation d'irbesartan
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2726917C (fr) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
WO2010009319A2 (fr) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
EP2194050A1 (fr) 2008-12-08 2010-06-09 KRKA, tovarna zdravil, d.d., Novo mesto Nouveau procédé pour la préparation d'irbesartan
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014151200A2 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
EP2970384A1 (fr) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
CN108276389B (zh) * 2018-02-09 2020-10-16 北京化工大学 一种厄贝沙坦的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
EP0409332A3 (en) * 1989-07-19 1991-08-07 Merck & Co. Inc. Substituted triazoles as angiotensin ii antagonists
DE69024556T2 (de) * 1989-07-28 1996-10-17 Merck & Co Inc Substituierte Triazolinone, Triazolinthione und Triazolinimine als Angiotensin II-Antagonisten

Also Published As

Publication number Publication date
CA2050769A1 (fr) 1992-03-11
IE913165A1 (en) 1992-03-11
HUT59129A (en) 1992-04-28
EP0475898A1 (fr) 1992-03-18
PT98903A (pt) 1992-07-31
NO913542L (no) 1992-03-11
JPH04342571A (ja) 1992-11-30
NO913542D0 (no) 1991-09-09
FI914228A (fi) 1992-03-11
KR920006323A (ko) 1992-04-27
FI914228A0 (fi) 1991-09-06
AU8375591A (en) 1992-03-12
ZA917143B (en) 1992-04-29
HU912903D0 (en) 1992-01-28

Similar Documents

Publication Publication Date Title
IL99372A0 (en) Azacyclic compounds
GB9012592D0 (en) Compounds
AP9100313A0 (en) Compounds
GB9001245D0 (en) Compounds
AP9100314A0 (en) Compounds
GB9011332D0 (en) Compounds
GB9009469D0 (en) Compounds
GB9007965D0 (en) Compounds
GB9007967D0 (en) Compounds
EP0441598A3 (en) Spiroisoindole compounds
ZA913859B (en) Azacyclic derivatives
GB9007738D0 (en) Compounds
IE892143L (en) Azacyclic compounds
ZA913166B (en) Azacyclic derivatives
GB9005671D0 (en) Compounds
GB9002932D0 (en) Compounds
GB9011693D0 (en) Compounds
GB9003640D0 (en) Compounds
GB9003641D0 (en) Compounds
GB9004320D0 (en) Compounds
GB9008556D0 (en) Compounds
GB9006449D0 (en) Compounds
GB9010266D0 (en) Compounds
GB9003044D0 (en) Compounds
GB9009485D0 (en) Compounds